Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer
This is an open-label, phase II study to evaluate the efficacy and safety of biweekly docetaxel and DeGramont regimen on unresectable gastric adenocarcinoma in the first-line therapy.
Gastric Adenocarcinoma
DRUG: Docetaxel|DRUG: Fluorouracil
Overall response rate according to RECIST 1.1, One Year
Time to progression, One year|Overall survival, One year|Incidence of grade 3 or 4 toxicity, The criteria to grade the toxicity is NCI CTC 3.0, One year
Primary endpoint: Overall Response Rate

Secondary endpoint: Time to progression, overall survival, safety data